Business

A personalised cancer vaccine has showed promise in its first ever late stage trial.

Moderna-Merck stock soars on cancer vaccine breakthrough

The experimental personalised cancer vaccine has showed positive initial results in its first-ever late-stage trial, particularly on its main goal of preventing the recurrence of melanoma.

Updated
Read more (3 min) →